📣 VC round data is live. Check it out!

abrdn Life Sciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for abrdn Life Sciences and similar public comparables like Djerriwarrh Investments, Deutsche Beteiligungs, Chrysalis Investments, CoinShares and more.

abrdn Life Sciences Overview

About abrdn Life Sciences

abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund’s Investment Adviser to have the potential for above-average growth.


Founded

1992

HQ

United States

Employees

N/A

Financials (FY)

Revenue: $86M
Net Income: $86M

EV

$523M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

abrdn Life Sciences Financials

abrdn Life Sciences reported last fiscal year revenue of $86M.

In the same fiscal year, abrdn Life Sciences generated $86M in net income.


abrdn Life Sciences P&L

In the most recent fiscal year, abrdn Life Sciences reported revenue of $86M and net income of $86M.

abrdn Life Sciences is profitable as of last fiscal year, with net margin of 99%.

See analyst estimates for abrdn Life Sciences
Last FY202320242025202620272028
Revenue$86M$39M$87M$86M
Net Profit$86M$38M$85M$86M
Net Margin99%97%99%99%

Financial data powered by Morningstar, Inc.

abrdn Life Sciences Stock Performance

abrdn Life Sciences has current market cap of $523M, and enterprise value of $523M.

Market Cap Evolution


abrdn Life Sciences' stock price is $17.19.

abrdn Life Sciences share price decreased by 1.8% in the last 30 days, and increased by 44.5% in the last year.

abrdn Life Sciences has an EPS (earnings per share) of $2.81.

See more trading valuation data for abrdn Life Sciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$523M$523M0.0%-1.8%3.2%44.5%$2.81

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

abrdn Life Sciences Valuation Multiples

abrdn Life Sciences trades at 6.1x EV/Revenue multiple.

See NTM and 2027E valuation multiples for abrdn Life Sciences

abrdn Life Sciences Financial Valuation Multiples

As of May 25, 2026, abrdn Life Sciences has market cap of $523M and EV of $523M.

abrdn Life Sciences has a P/E ratio of 6.1x.

Last FY202320242025202620272028
EV/Revenue6.1x13.3x6.0x6.1x
P/E6.1x13.7x6.1x6.1x
EV/FCF16.5x16.5x16.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified abrdn Life Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

abrdn Life Sciences Margins & Growth Rates

In the most recent fiscal year, abrdn Life Sciences reported net margin of 99%.

See estimated margins and future growth rates for abrdn Life Sciences

abrdn Life Sciences Margins

Last FY20242025202720282029
Net Margin99%99%99%
FCF Margin37%37%37%

abrdn Life Sciences Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth120%(0%)
Net Profit Growth124%0%
FCF Growth0%

Data powered by FactSet, Inc. and Morningstar, Inc.

abrdn Life Sciences Operational KPIs

Access forward-looking KPIs for abrdn Life Sciences
Last FY202320242025202620272028
G&A Expenses to Revenue1%3%1%1%
Opex to Revenue1%3%1%1%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

abrdn Life Sciences Competitors

abrdn Life Sciences competitors include Djerriwarrh Investments, Deutsche Beteiligungs, Chrysalis Investments, CoinShares, Eagle Point Credit, SPARX Group, Hedge Brasil Shopping FII, Brait, Nextensa and SBI Global Asset Management.

Most abrdn Life Sciences public comparables operate across Asset Management.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Djerriwarrh Investments17.1x
Deutsche Beteiligungs5.7x6.8x16.0x15.0x
Chrysalis Investments3.7x68.4x
CoinShares
Eagle Point Credit4.0x4.2x
SPARX Group4.2x3.8x9.0x
Hedge Brasil Shopping FII9.6x8.0x
Brait18.8x

This data is available for Pro users. Sign up to see all abrdn Life Sciences competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About abrdn Life Sciences

When was abrdn Life Sciences founded?abrdn Life Sciences was founded in 1992.
Where is abrdn Life Sciences headquartered?abrdn Life Sciences is headquartered in United States.
Is abrdn Life Sciences publicly listed?Yes, abrdn Life Sciences is a public company listed on NYSE.
What is the stock symbol of abrdn Life Sciences?abrdn Life Sciences trades under HQL ticker.
Who are competitors of abrdn Life Sciences?abrdn Life Sciences main competitors include Djerriwarrh Investments, Deutsche Beteiligungs, Chrysalis Investments, CoinShares, Eagle Point Credit, SPARX Group, Hedge Brasil Shopping FII, Brait, Nextensa, SBI Global Asset Management.
What is the current market cap of abrdn Life Sciences?abrdn Life Sciences' current market cap is $523M.
What is the current revenue of abrdn Life Sciences?abrdn Life Sciences' last fiscal year revenue is $86M.
What is the current EV/Revenue multiple of abrdn Life Sciences?Current revenue multiple of abrdn Life Sciences is 6.1x.
Is abrdn Life Sciences profitable?No, abrdn Life Sciences is not profitable.
How many companies abrdn Life Sciences has acquired to date?abrdn Life Sciences hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies abrdn Life Sciences has invested to date?abrdn Life Sciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to abrdn Life Sciences

Lists including abrdn Life Sciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial